Table 3.
USgHIFU treatment results of lesions
| Variable | Baseline | 1st day | 3rd day | 7thday |
| ALT (U l–1) | 17.9 ± 6.2 (9.3–27.3) | 17.0 ± 7.1 (10.0–31.7) | 17.1 ± 5.8 (10.1–27.2) | 17.1 ± 5.7 (10.3–27.1) |
| AST (U l–1) | 18.9 ± 3.8a(13.0–25.0) | 24.0 ± 6.4a(16.7–40.8) | 20.1 ± 4.4 (14.6–30.7) | 19.1 ± 3.7 (14.4–27.8) |
| TB (umol l–1) | 9.5 ± 4.8b(4.5–19.9) | 12.9 ± 5.3b(6.3–23.0) | 11.0 ± 5.1 (5.1–22.0) | 10.4 ± 4.3 (4.9–20.5) |
| Serum creatinine (μmoll l–1) | 58.7 ± 6.5 (48.5–75.1) | 55.2 ± 8.3 (48.3–76.0) | 58.1 ± 5.9 (48.7–75.8) | 57.9 ± 5.6 (47.5–72.9) |
| Blood ureain (U l–1) | 4.2 ± 1.1 (2.6–6.4) | 3.8 ± 0.8 (2.9–5.7) | 4.1 ± 0.6 (2.8–6.1) | 4.0 ± 0.5 (3.0–5.9) |
| HB (g l–1) | 120.4 ± 21.5 (86–169) | 121.3 ± 19.0 (91–161) | 121.9 ± 18.3 (94–158) | 120.0 ± 18.9 (93-157) |
| WBC(109 l–1) | 5.8 ± 1.6c(3.5–8.6) | 7.2 ± 2.0c(4.8–11.0) | 6.5 ± 1.9 (5.1–7.4) | 6.0 ± 1.7 (4.0–8.3) |
| PLT(109 l–1) | 231.2 ± 49.6 (146–310) | 227.5 ± 47.6 (154–305) | 230.5 ± 45.5 (158–300) | 231.8 ± 47.1 (159–290) |
| PT (s) | 13.3 ± 0.9 (12.1–14.7) | 13.8 ± 0.7 (12.7–15.1) | 13.6 ± 0.5 (13.1–14.2) | 13.7 ± 1.2 (12.0–14.9) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HB, haemoglobin; PLT, platelet; PT, prothrombin times; SSS, symptom severity scores; TB, total bilirubin; UFS-QOL, The Uterine Fibroid Symptom and Quality of Life; USgHIFU, ultrasound-guided high-intensity focused ultrasound; WBC, white blood cells.
ap = 0.028.
bp = 0.032.
cp = 0.046.